Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
BHP Faces AU$1.3 Billion Wage Adjustment for Queensland...
​Royal Gold to Create Streaming and Royalty Giant...
Chris Berry: The West Must Invest in Refinement...
Torex Gold Moves Beyond Single-Asset Status With Reyna...
Ekin Ober on Why AI Could Be Mining’s...
Maritime Resources: A Low-risk Path to Gold Production...
Stallion Uranium Provides Update on Technology Data Acquisition...
Trump Tariffs to Raise US Medical Device Costs,...
EVs Now Emit 73 percent Less Than Gasoline...
OpenAI to release web browser in challenge to...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

5 Small-cap Biotech ETFs to Watch (Updated 2024)

by admin August 17, 2024
August 17, 2024
5 Small-cap Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.

ETFs are a popular choice as they allow investors to enter the market more safely compared to investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

All other figures were also current as of that date. Read on to learn more about these investment vehicles.

1. ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB)

Company Profile

AUM: US$87.99 million

The ProShares Ultra NASDAQ Biotechnology ETF was launched in April 2010 and is leveraged to offer twice daily long exposure to the broad-based NASDAQ Biotechnology Index, making it an ideal choice “for investors with a bullish short-term outlook for biotechnology or pharmaceutical companies.” However, analysts also advise investors with a low risk tolerance or a buy-and-hold strategy against investing in this fund due to its unique nature.

Of the 218 holdings in this ETF, the top biotech stocks in the ETF are Regeneron Pharmaceuticals (NASDAQ:REGN) at a 6.01 percent, Gilead Sciences (NASDAQ:GILD) at 5.97 percent and Amgen (NASDAQ:AMGN) at 5.49 percent.

2. Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Company Profile

AUM: US$82.83 million

The Global X Genomics & Biotechnology ETF tracks genomic science stocks, such as companies focused on gene editing, genomic sequencing, genetic medicine and therapy, computational genomics and biotechnology. This fund was first introduced to the market in April 2019 and invests at least 70 percent of its assets in mid- and small-cap companies.

There are 43 holdings in this biotech fund. Its top holdings include Alnylam Pharmaceuticals (NASDAQ:ALNY) at a weight of 6.73 percent, Avidity Bioscience (NASDAQ:RNA) with a weight of 5.29 percent and Legend Biotech (NASDAQ:LEGN) at 4.52 percent.

3. Tema Obesity and Cardiometabolic ETF (NASDAQ:HRTS)

Company Profile

AUM: US$81.7 million

Launched in November 2023, the Tema Obesity and Cardiometabolic ETF tracks biotech stocks with a focus on diabetes, obesity and cardiovascular diseases. The fund was renamed on March 25; previously it was known as the Tema Cardiovascular and Metabolic ETF. More than three-quarters of its holdings are based in the US.

There are 46 holdings in this biotechnology fund, with about a 50/50 split between small- to mid-cap stocks and large-cap companies. Its top holdings include Alnylam Pharmaceuticals, Amgen at 5.65 percent and Eli Lilly and Company (NYSE:LLY) at 5.56 percent.

4. Tema Oncology ETF (NASDAQ:CANC)

Company Profile

AUM: US$47.94 million

The Tema Oncology ETF provides exposure to biotech companies operating in the oncology industry. It includes companies developing a range of cancer treatments, including CAR-T cell therapies and bispecific antibodies.

Launched in August 2023, this biotechnology fund has 49 holdings, with about 46 percent being small- to mid-cap stocks and 4.6 percent being micro stocks. Among its top holdings are Regeneron Pharmaceuticals at a weight of 6.1 percent, AstraZeneca (NASDAQ:AZN) at 5.87 percent and argenx SE (NASDAQ:ARGX) at 4.55 percent.

5. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Company Profile

AUM: US$20.88 million

The Virtus LifeSci Biotech Products ETF tracks the performance of US-listed biotech stocks with at least one drug therapy approved by the US Food and Drug Administration or in the late stages of clinical development.

Over 70 percent of its holdings are in small- and mid-cap stocks and over 85 percent of its holdings are US companies. Its top holdings are Alnylam Pharmaceuticals at 2.64 percent, Mirum Pharmaceuticals (NASDAQ:MIRM) at 2.35 percent and ADMA Biologics (NASDAQ:ADMA) at 2.32 percent.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

previous post
Top 10 Countries for Natural Gas Production (Updated 2024)
next post
Trident Royalties PLC Announces Holding in Company

You may also like

Strong drilling results point to growth and upgrades...

March 18, 2025

Triumph Gold: Multi-million-ounce, District-scale Gold Assets in the...

May 7, 2025

Olympio to Acquire Canadian Copper-Gold Project on Prolific...

November 19, 2024

Mawson Finland Announces Upsize of Brokered Private Placement

February 15, 2025

Investing in Graphene Companies

January 8, 2025

Helium Evolution

August 27, 2024

High grade gold in early stage drilling at...

July 3, 2025

Crypto Market Recap: Coinbase Hit by US$400 Million...

May 17, 2025

Top 10 Gold Reserves by Country

November 22, 2024

Can You Invest in Elon Musk’s Neuralink? (Updated...

August 22, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • BHP Faces AU$1.3 Billion Wage Adjustment for Queensland Coal Miners

      July 11, 2025
    • ​Royal Gold to Create Streaming and Royalty Giant in US$3.7 Billion Deal

      July 11, 2025
    • Chris Berry: The West Must Invest in Refinement Now or Fall Further Behind

      July 11, 2025
    • Torex Gold Moves Beyond Single-Asset Status With Reyna Silver Takeover

      July 11, 2025
    • Ekin Ober on Why AI Could Be Mining’s Most Valuable Tool Yet

      July 11, 2025
    Promotion Image

    banner ads

    Categories

    • Business (764)
    • Economy (829)
    • Investing (2,387)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved